Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.54 +1.8%	$4.45	$3.00 ▼ $25.45	$219.57M	0.3	1.74 million shs	1.61 million shs
HRTX Heron Therapeutics	$1.33 -1.5%	$1.93	$1.04 ▼ $2.68	$203.88M	1.15	2.12 million shs	1.78 million shs
IFRX InflaRx	$0.86 +4.3%	$0.84	$0.71 ▼ $2.82	$57.93M	1.29	209,557 shs	197,844 shs
OGI Organigram Global	$1.43 -8.3%	$1.43	$0.85 ▼ $2.08	$191.66M	1.45	913,543 shs	1.07 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	0.00%	+1.11%	-1.09%	+10.19%	-72.52%
HRTX Heron Therapeutics	0.00%	+0.76%	-33.50%	-32.49%	-28.49%
IFRX InflaRx	0.00%	+7.84%	-0.58%	-48.02%	-36.08%
OGI Organigram Global	0.00%	-1.04%	-2.05%	+5.15%	-24.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.3362 of 5 stars	2.9	0.0	0.0	2.7	1.7	1.3
HRTX Heron Therapeutics	4.1562 of 5 stars	3.2	1.0	4.2	3.4	3.3	0.6
IFRX InflaRx	3.3816 of 5 stars	3.5	4.0	0.0	3.8	1.7	0.6
OGI Organigram Global	0.3961 of 5 stars	0.0	2.0	0.0	1.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	239.21% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	238.35% Upside
IFRX InflaRx	3.00	Buy	$6.60	664.86% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IFRX, CRGX, HRTX, and OGI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
HRTX Heron Therapeutics	$149.69M	1.36	N/A	N/A	($0.18) per share	-7.39
IFRX InflaRx	$180K	321.81	N/A	N/A	$0.96 per share	0.90
OGI Organigram Global	$117.47M	1.63	N/A	N/A	$2.08 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	N/A
IFRX InflaRx	-$49.85M	-$0.80	N/A	N/A	N/A	N/A	-71.76%	-57.68%	N/A
OGI Organigram Global	-$33.39M	$0.05	28.61	N/A	N/A	2.86%	-8.19%	-5.79%	N/A

Latest IFRX, CRGX, HRTX, and OGI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	-$0.24	N/A	-$0.24	$0.02 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	12.37	12.37
HRTX Heron Therapeutics	N/A	0.82	1.76
IFRX InflaRx	N/A	4.10	3.78
OGI Organigram Global	N/A	2.59	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
HRTX Heron Therapeutics	80.01%
IFRX InflaRx	42.39%
OGI Organigram Global	34.63%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
HRTX Heron Therapeutics	5.86%
IFRX InflaRx	16.30%
OGI Organigram Global	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
OGI Organigram Global	860	134.03 million	133.91 million	Optionable

IFRX, CRGX, HRTX, and OGI Headlines

Recent News About These Companies

Atb Cap Markets Issues Pessimistic Forecast for OGI Earnings

August 17 at 11:31 AM | marketbeat.com

OGI FY2025 EPS Forecast Reduced by Alliance Global Partners

August 17 at 10:02 AM | marketbeat.com

FY2028 Earnings Estimate for OGI Issued By Atb Cap Markets

August 17 at 3:19 AM | americanbankingnews.com

Organigram Global (NASDAQ:OGI) Cut to Sell at Wall Street Zen

August 17 at 2:15 AM | marketbeat.com

OGI FY2025 EPS Decreased by Alliance Global Partners

August 17 at 2:13 AM | americanbankingnews.com

Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

Organigram reports Q3 revenue $70.8M, consensus $68.04M

August 13, 2025 | msn.com

Organigram Posts Wider Loss, Eyes Profitability In Near Term

August 13, 2025 | benzinga.com

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

Organigram Reports Record Third Quarter Fiscal 2025 Results

August 13, 2025 | financialpost.comF

Organigram Global (OGI) Expected to Announce Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Organigram Global (OGI) to Release Quarterly Earnings on Wednesday

August 6, 2025 | marketbeat.com

Organigram Global (NASDAQ:OGI) Trading Up 3.8% - Should You Buy?

August 5, 2025 | marketbeat.com

Organigram Global Inc. (OGI) Expands Into U.S. THC Beverage Market Across 25 States

August 2, 2025 | msn.com

Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

August 1, 2025 | financialpost.comF

Organigram Global Inc. (OGI) Stock Price Today - WSJ

July 15, 2025 | wsj.com

Shareholders in Organigram Global (TSE:OGI) are in the red if they invested five years ago

July 9, 2025 | finance.yahoo.com

Organigram Expands U.S. Presence with Hemp-Derived THC Beverage Launch

July 8, 2025 | tipranks.com

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | financialpost.comF

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | businesswire.com

OGI Organigram Global Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, CRGX, HRTX, and OGI Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.54 +0.08 (+1.79%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.54 +0.00 (+0.09%)

As of 08/15/2025 06:07 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Heron Therapeutics NASDAQ:HRTX

$1.33 -0.02 (-1.48%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.03 (+2.63%)

As of 08/15/2025 07:14 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

InflaRx NASDAQ:IFRX

$0.86 +0.04 (+4.30%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.86 0.00 (-0.57%)

As of 08/15/2025 07:27 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Organigram Global NASDAQ:OGI

$1.43 -0.13 (-8.33%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.03 (+1.75%)

As of 08/15/2025 07:19 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time